Analysts Offer Insights on Healthcare Companies: Zimmer Biomet Holdings (ZBH) and 20/20 Biolabs, Inc. (AIDX)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Zimmer Biomet Holdings (ZBH) and 20/20 Biolabs, Inc. (AIDX) with bullish sentiments.
Claim 30% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Zimmer Biomet Holdings (ZBH)
TD Cowen analyst Mathew Blackman maintained a Buy rating on Zimmer Biomet Holdings today and set a price target of $109.00. The company’s shares closed last Monday at $87.80.
According to TipRanks.com, Blackman is a 4-star analyst with an average return of
Currently, the analyst consensus on Zimmer Biomet Holdings is a Hold with an average price target of $100.38.
See today’s best-performing stocks on TipRanks >>
20/20 Biolabs, Inc. (AIDX)
Alliance Global Partners analyst Brian Kinstlinger maintained a Buy rating on 20/20 Biolabs, Inc. today and set a price target of C$2.25. The company’s shares closed last Monday at $1.99, close to its 52-week low of $1.70.
According to TipRanks.com, Kinstlinger is a 5-star analyst with an average return of
20/20 Biolabs, Inc. has an analyst consensus of Moderate Buy, with a price target consensus of $1.82, which is a -12.5% downside from current levels. In a report issued on March 11, Stifel Nicolaus also maintained a Buy rating on the stock with a C$3.10 price target.
Read More on ZBH:
Disclaimer & DisclosureReport an Issue
- Zimmer Biomet’s Mymobility Study: Fresh Clinical Data on a Digital Edge in Joint Replacement
- Super Micro downgraded, MongoDB upgraded: Wall Street’s top analyst calls
- Zimmer Biomet downgraded to Neutral from Buy at BTIG
- Zimmer Biomet’s New Knee Implant Study Builds a Quiet Catalyst for Long-Term Growth
- Zimmer Biomet’s ROSA Knee v1.5 Pilot Study: What the Latest Update Signals for ZBH Investors
